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Monoclonal antibodies are large molecules with complex structure and functions. They have a wide
application for treatment of a broad range of chronic diseases and represent the largest class of bio-
therapeutic products. Given that biotherapeutic products may induce unwanted humoral and/or cellular
immune responses in recipients, it is essential to investigate the immunogenicity of a product prior to
licensure. The immune response is inﬂuenced by many factors and data generated in the pre-licensure
studies are usually somewhat difﬁcult for regulatory review. The knowledge and expertise required
for this requires a thorough understanding of animal and human immunology as well as speciﬁc product
characteristics, including mechanism of action, antibody assays and assessment of results in a given
clinical context. The appropriate interpretation of immunogenicity data is of critical importance for
deﬁning the safety proﬁle of a monoclonal antibody.
Two case studies described in this paper were prepared to mimic a real situation in which regulators
need to evaluate immunogenicity studies conducted by manufacturers of monoclonal antibody products.
The speciﬁc objective of the case studies was to illustrate assessment of unwanted immunogenicity and
the important factors that need to be considered in this context. Regulators and manufacturers who
attended the World Health Organization (WHO) implementation workshop on Evaluation of Bio-
therapeutic Products, held in Seoul, Republic of Korea, in May 2014, participated in the case studies and
provided valuable input. This article outlines the main aspects of immunogenicity discussed in these case
studies and a summary of the lessons learned at this occasion.
© 2015 The Authors. Published by Elsevier Ltd on behalf of The International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Monoclonal antibodies (mAbs) have very considerable potential
for therapeutic use and are the largest class of biotherapeutic
products. Although most are potent products with clear clinical
efﬁcacy, some are associated with adverse effects. A potential
problem with the in-vivo use of mAbs is induction of unwanted
immunogenicity, usually most clearly manifest as production of
antibodies against the mAb. This can cause safety issues such as
anaphylactoid problems of varying severity and also impact on
efﬁcacy, rendering the product less or non-efﬁcacious. Assessment
of immunogenicity is now regarded as an essential part of product
development. Evidence shows that the incidence ofLtd on behalf of The International A
y-nc-nd/4.0/).immunogenicity, its characteristics and clinical consequences vary
considerably and this is affected by many different factors [1e4].
However, prediction of whether a product will be immunogenic
and how this will affect safety and particularly efﬁcacy is difﬁcult, if
not impossible [5]. In view of this, it is necessary to assess un-
wanted immunogenicity directly by carrying out immunogenicity
studies. Such studies involve screening patients for antibody
development normally as part of clinical trials. It is also important
that immunogenicity studies include an assessment of how anti-
body development impacts on clinical efﬁcacy and safety, and
appropriate methods for this must be adopted [1e6]. Immunoge-
nicity studies need to be evaluated to assess whether immunoge-
nicity is a problem for the clinical use of a product and results need
to be taken into account when using the product.
In 2013, the WHO Expert Committee on Biological Standardi-
zation (ECBS) adopted WHO guidelines on the quality, safety andlliance for Biological Standardization. This is an open access article under the CC BY-
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nant DNA technology [5]. During this meeting, members proposed
that WHO provides further assistance on immunogenicity assess-
ment including screening/conﬁrmation/neutralizing assays and
data interpretation in implementation workshops. Furthermore,
some regulators have expressed the opinion that they ﬁnd various
problems with assessing immunogenicity studies. These are prob-
lems with assessing the strategy adopted, with evaluating the types
of assays used, with evaluating the data generated, with assessing
the meaning of the results obtained and with assessing how the
ﬁndings impact on the clinical safety and efﬁcacy of the product.
The 1st WHO implementation workshop for the newly adopted
guidelines was held from 13 to 14 May 2014 in Seoul, Republic of
Korea, and two case studies were intentionally developed for the
purpose of training for a better understanding of principles relating
especially to immunogenicity assessment as outlined in section
C.6 of the Guidelines [5]. Since monoclonal antibody products were
identiﬁed as the most complex and difﬁcult biotherapeutics for
evaluation, mAbs were selected as subjects for these case studies.
The strategy adopted for assessing unwanted immunogenicity
normally involves a stepwise application of methods. As described
in the WHO guidelines [5] a “highly sensitive screening assay
should be used for antibody detection and a conﬁrmatory assay
should be used to conﬁrm the presence of antibodies and eliminate
false positive results”. Also, a “neutralization assay should be
available for further characterization of antibodies”. Although no
single strategy is mandatory and details of this may differ according
to products assessed etc., some general principles apply and a
tiered approach for this is normally adopted. A screening immu-
noassay is usually used to assess all samples from all individuals for
the presence of antibodies and then a conﬁrmatory assay is used to
conﬁrm positives i.e. eliminate false positives. Conﬁrmed positive
samples are then normally assessed for neutralizing activity using a
bioassay or surrogate for this. The clinical consequences of induced
antibodies also need to be assessed [1,2,5e10].
Tumour necrosis factor (TNF)-alfa is a cytokine with potent pro-
inﬂammatory activity. Not only is it involved in inﬂammation, but is
also a stimulatory immunomodulator, and is involved in the
development of immune responses e.g. against infectious agents.
Inappropriate production of TNF-alfa (usually along with other
inﬂammatory substances) can result in inﬂammatory disorders
such as Rheumatoid Arthritis, Irritable Bowel Disease (IBD), Crohn's
disease, some forms of psoriasis etc. Undesirable involvement of
TNF-alfa in these diseases clearly identiﬁes anti-TNFs as a thera-
peutic option for their treatment and mAbs which neutralize the
activity of TNF are currently used for such clinical intervention.
Some examples of these are inﬂiximab (Remicade), adalimumab
(Humira), certolizumab pegol (Cimzia), golimumab (Simponi).
CD20 is a cell-surface marker expressed on mature B cells and
most malignant B cells.
It is involved in B cell maturation, but seems to have no natural
ligand. Targeting CD-20 for treatment of numerous B-cell leukae-
mias has been shown to be effective and several mAbs have been
used for this e.g. rituximab (Rituxan, MabThera and Zytux), ofatu-
mumab (Arzerra), tositumomab (Bexxar) and ibritumomab tiux-
etan (Zevalin). The mechanism for action of such mAbs in this is
binding of the mAb to CD-20 followed by killing/clearing of ma-
lignant cells expressing the antigen.
2. Methodology
Two case studies were prepared for the WHO implementation
workshop in order to understand the principles for evaluation of
immunogenicity studies aimed at assessing the unwanted immu-
nogenicity of mAbs outlined in WHO Guidelines [5].Immunogenicity studies for two different mAbs are considered.
These mAb products, called mAbX and mAbY are produced taking
account of the WHO guidelines [5] and are intended for in vivo
clinical use in humans. The information and data in these case
studies are ﬁctitious and do not represent products approved or
under development. The scenarios of case studies are intended to
outline evaluation principles in immunogenicity assessment and
data interpretation of immunogenicity of biotherapeutics, in
particular monoclonal antibody products. In addition, the assay
methods used in these case studies are limited, so other methods
should be considered in the actuality of immunogenicity
assessment.
In order to practice the case studies through group discussions,
workshop participants including 40 regulators from 22 countries
and 20manufacturers (see acknowledgements section) took part in
the case study exercise during the workshop. Their expertise
covered the quality, nonclinical and clinical parts of the develop-
ment and regulation of biotherapeutic products. Participants were
divided into 8 groups, i.e. 8 persons/group, comprising even dis-
tribution between WHO regions, regulators vs. manufacturers,
gender ratio and expertise in quality and clinical assessment. Two
facilitators per group were appointed. Four groups (group 1e4)
were asked to focus on assessment of mAbX and the remaining four
(group 5e8) to focus on mAbY. Two questions were given to each
group to allow at least 2 groups to work on the same questions. The
plan for the group-work was sent to all participants 10 days before
the workshop.
2.1. Questions asked of participants
After considering the case studies, participants were asked to
address/answer the following questions:
1. Study design:
a. if you are a regulator, would you approve study design for
mAbX/mAbY? Explain the pros and cons;
b. if you are manufacturer, would you proceed with such study
design for mAbX/mAbY? Explain the pros and cons.
2. Are the assays appropriate for immunogenicity assessment of
mAbX/mAbY?
3. On the basis of the results would you consider that the immu-
nogenicity proﬁle of mAbX/mAbY:
a. is acceptable for the intended use?
b. should be further investigated?
c. is not acceptable for the intended use?
4. Following application submission using the stand-alone
approach for mAbX, the product was approved for treatment
of rheumatoid arthritis (RA). Sometime later, the manufacturer
wishes to increase the indications for treatment to include
Crohn's disease and IBD. Would you consider the current
immunogenicity study suitable for that purpose? Elaborate on
this.
5. The manufacturer of mAbY is considering conducting clinical
trials to evaluate the product for use in inducing immunosup-
pression in patients suffering from autoimmune diseases. Will
new immunogenicity studies be neededwith these or would the
existing studies with leukaemia patients be sufﬁcient? Explain
the pros and cons.
3. Description of case studies
3.1. mAbX
MAbX is a human mAb speciﬁc for human TNF-alpha. It was
made using phage display technology followed by production as an
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for use in treating rheumatoid arthritis. It resembles adalimumab
except for its sublass (IgG4).
The reason for producing an IgG4mAb is that immunobiological
activity should be reduced compared to IgG1 mAbs (like adalimu-
mab), with the possibility of less adverse effects including
infections.
Patients received mAbX intravenously at 6 week intervals for 4
cycles. Blood was taken for analysis after cycles 2, 3 and 4.3.1.1. Immunogenicity assessment of mAbX
Immunogenicity assessment was conducted as outlined in the
WHO ‘Guidelines on the quality, safety, and efﬁcacy of bio-
therapeutic protein products prepared by recombinant DNA tech-
nology’. For this a tiered approach was taken involving a screening
assay followed by a conﬁrmatory assay to eliminate false positives
[1,2,6e10].
The assays used for this were:
a) Screening electrochemiluminescence immunoassay (ECL assay)
For this, wells of streptavidin coated microtitre plates were
incubated with biotin conjugated mAbX. After washing, samples
(positive and negative controls, patient serum samples) were
added to the wells and incubated prior to washing and incubation
with Ruthenium conjugated mAbX. After addition of luminescence
reagents the assay was analysed using a Meso Scale Discovery
(MSD) instrument. Background signal was subtracted from all
values.
b) Conﬁrmation (ECL competition assay)
This was carried out as for the screening assay except samples
were incubated for 1 h with an excess of unlabelled mAbX prior to
addition to mAbX coated wells.
Continuing with the tiered approach [6], conﬁrmed positives
were assessed for neutralizing capacity using a competitive ligand
binding (CLB) assay as follows:
c) CLB assay
For this, rDNA derived biologically active TNF-alpha was
immobilized onto wells of microtitre plates. This was achieved by
initially coating the wells with a non-neutralizing mAb speciﬁc for
TNF-alpha that bound to an epitope remote from the receptor
binding site followed by incubation with TNF-alpha. After washing
and blocking, a mixture of samples (positive and negative controls,
patient serum samples) and horse radish peroxidase labelled mAbX
were added to the wells, incubated, washed and bound horse
radish peroxidase (HRP) detected using appropriate substrate. The
absorbance of wells was measured using an automated plate
reader.
As no human antibodies against mAbX were available for vali-
dation the assays were validated using animal sera raised using
mAbX as immunogen.
The background readout of these assays was established by
assaying 50 serum samples obtained from ‘normal’ individuals.
For immunogenicity assessment, a study was conducted using
serum samples collected from RA patients who were taking part in
a large clinical efﬁcacy trial. The trial included 297 patients and
blood samples were taken on 3 subsequent occasions 2 weeks after
administration of mAbX product. Serum was separated as soon as
possible after venepuncture and stored in aliquots at 40 C prior
to analysis. Serum was assayed at a dilution of 1:20.For the screening assay a reading of above 37 U was considered
positive.
Data from this is shown in Table 1 and were assessed to estab-
lish: a) assay performance; b) number of antibody positive in-
dividuals (calculate % positives); and c) any problemswith samples/
the assay.
No patients had antibodies to mAbX prior to treatment.
Positive sera from the screen were conﬁrmed using the conﬁr-
matory assay. Results from this are shown in Table 2 and were
assessed to establish: a) assay performance; and b) how many of
the positive individuals in the screening assay are conﬁrmed
positive.
A reduction in signal of greater than 25% compared to uncom-
peted signal was considered a conﬁrmation of positivity.
A proportion of the positive sera were titered. The tested sera
showed a dose response and titre correlated with the screening
assay data.
The conﬁrmed positive samples were assessed for neutralizing
capacity in the CLB assay as shown in Table 3. Datawere assessed to
establish: a) assay performance; and b) howmany of the conﬁrmed
positive individuals in the screening assay produce neutralizing
responses.
A reduction in absorbance of >10% of the uninhibited value was
considered a positive result.
3.1.2. Correlation of antibody induction with clinical effects of
mAbX
Some patients experienced adverse effects apparently associ-
ated with mAbX therapy.
This included anaphylactoid and administration site effects.
Patients affected were as shown in Table 4. Some patients
showed diminished response to therapy as treatment progressed as
shown in Table 4. In the antibody negative population, 1 patient
experienced adverse effects (site reaction) and 3 patients showed
low response to therapy.
Data were assessed to show whether antibody development
causes adverse clinical effects as well as what the clinical effects are
caused by, i.e. binding antibodies or neutralizing antibodies.
3.2. mAbY
MAbY is a chimeric mAb speciﬁc for human CD 20, an antigen
predominantly found on the surface of cells of the B lymphocyte
lineage. It was made by fusing the mouse variable region genes
from a hybridomawhich secretes a human CD20 speciﬁc mAbwith
the gene for the human IgG1 Fc region or the human kappa light
chain constant region. It is intended for use in treating various B-
cell leukaemias. Its International Nonproprietary Names (INN) is
rituximab, and it is similar to existing CD-20 mAbs. The manufac-
turer is pursuing stand-alone development for marketing in
numerous regions.
Patients received mAbY intravenously at weekly intervals for 6
cycles. Blood was taken for analysis after cycles 2 and 6.
3.2.1. Immunogenicity assessment of mAbY
Immunogenicity assessment was conducted as outlined in the
WHO ‘Guidelines on the quality, safety, and efﬁcacy of bio-
therapeutic protein products prepared by recombinant DNA tech-
nology’ [1,2,5e10].
For this a tiered approach was taken involving a screening assay
followed by a conﬁrmatory assay to eliminate false positives.
The assays used for this were:
a) Screening immunoassay (direct enzyme-linked immunosorbent
assay (ELISA))
Table 1
Screening assay results for mAbX.
Sample ECL signal Sample ECL signal Sample ECL signal
1 12000,14000,900 50 35,188,1200 99 29,30,19
2 19,24,22 51 21,23,19 100 22,24,26
3 20,23,20 52 25,23,22 101 28,29,25
4 24,23,21 53 2000,15000,1600 102 21,19,23
5 25,25,24 54 19,22,24 103 22,26,27
6 23,26,25 55 22,23,25 104 28,26,25
7 25,21,20 56 28,23,24 105 22,20,20
8 23,18,19 57 19,19,20 106 9000,12000,10000
9 25,23,22 58 22,23,21 107 21,22,22
10 20,23,19 59 25,26,28 108 26,24,24
11 34,2470,2360 60 22,22,23 109 27,25,22
12 19,23,30 61 1890,17000,15000 110 28,26,29
13 25,26,19 62 22,25,23 111 19,24,27
14 23,23,21 63 19,22,26 112 8000,7000,500
15 25,17,19 64 26,23,21 113 22,25,27
16 21,20,21 65 22,26,23 114 21,20,31
17 24,26,21 66 21,22,21 115 23,28,30
18 19,19,18 67 24,22,21 116 22,22,20
19 21,22,25 68 22,25,26 117 21,26,19
20 25,21,22 69 21,23,25 118 23,27,21
21 22,25,21 70 21,22,20 119 22,21,20
22 24,1570,33 71 23,24,21 120 26,29,30
23 19,21,22. 72 90,130,140 121 23,21,26
24 21,26,24 73 21,22,21 122 5000,4000,4200
25 180,2780,2900 74 25,23,22 123 23,28,19
26 23,21,18 75 27,25,27 124 21,27,30
27 25,22,19 76 21,22,21 125 25,26,21
28 27,26,28 77 28,25,26 126 22,20,25
29 19,18,21 78 22,21,20 127 21,26,29
30 1900,2100,2340 79 22,20,21 128 28,29,23
31 23,1200,19 80 21,26,19 129 21,20,19
32 22,22,24 81 19,23,22 130 27,31,21
33 21,19,20 82 22,23,22 131 25,26,22
34 19,19,25 83 28,19,21 132 2000,10000,11000
35 19,23,24 84 20,21,20 133 21,21,27
36 25,29,27 85 23,25,24 134 28,27,19
37 22,23,18 86 21,21,27 135 22,23,27
38 21,27,23 87 23,28,19 136 19,18,19
39 25,26,23 88 18,19,20 137 21,28,30
40 22,23,23 89 21,22,20 138 20,25,31
41 20,23,21 90 28,22,21 139 21,22,28
42 21,24,23 91 23,27,19 140 28,23,23
43 19,21,24 92 26,24,23 141 25,26,25
44 21,22,22 93 28,19,18 142 22,19,19
45 25,23,22 94 22,23,22 143 22,22,23
46 19,19,19 95 21,19,20 144 1000,5000,2000
47 23,24,22 96 20,22,21 145 21,30,31
48 21,21,22 97 11000,12000,12500 146 19,18,31
49 24,24,21 98 7000,10000,12000 147 26,28,19
148 22,22,23 198 19,23,27 248 22,23,19
149 21,19,26 199 23,19,31 249 Withdrawn
150 31,28,22 200 28,20,22 250 26,18,29
151 29,24,20 201 23,22,25 251 1000,5000,10200
152 4000,4000,4500 202 29,27,19 252 31,24,20
153 25,31,30 203 18,28,20 253 27,24,21
154 29,21,22 204 22,23,21 254 1000,9000,150
155 28,18,22 205 1000,2000,4000 255 26,26,28
156 31,27,19 206 22,27,18 256 19,20,27
157 22,20,31 207 26,20,28 257 28,23,26
158 27,24,26 208 18,19,19 258 22,31,30
159 23,31,19 209 28,31,28 259 28,25,29
160 11000,9000,4000 210 2000,17000,22000 260 26,21,28
161 22,19,29 211 19,26,28 261 21,22,30
162 23,24,28 212 27,23,29 262 30,31,27
163 20,19,19 213 23,21,18 263 26,20,28
164 23,28,21 214 20,20,21 264 22,22,21
165 28,31,32 215 26,31,30 265 4000,5000,7000
166 31,28,26 216 19,18,17 266 500,1500,8000
167 21,20,29 217 28,28,29 267 22,24,28
168 22,22,21 218 26,19,20 268 29,20,30
169 21,19,19 219 22,22,23 269 25,24,21
170 26,23,28 220 28,27,24 270 28,30,21
171 1000,5000,17000 221 19,21,20 271 21,28,20
172 22,20,26 222 28,25,31 272 29,20,21
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Table 1 (continued )
Sample ECL signal Sample ECL signal Sample ECL signal
173 28,24,18 223 31,20,23 273 28,23,22
174 18,22,20 224 27,24,29 274 19,18,20
175 1000,2000,500 225 21,20,25 275 22,22,23
176 21,31,31 226 22,28,30 276 27,24,29
177 28,19,20 227 28,31,20 277 2000,2400,10200
178 22,23,25 228 22,22,23 278 22,25,18
179 28,23,19 229 27,29,27 279 28,30,20
180 18,23,27 230 28,21,20 280 20,30,31
181 20,20,25 231 21,31,31 281 28,20,19
182 21,28,20 232 28,26,23 282 10000,15000,60000
183 28,25,19 233 100,500,2100 283 23,22,30
184 19,18,19 234 31,29,22 284 31,27,29
185 22,23,29 235 28,24,19 285 23,30,19
186 19,18,21 236 21,22,23 286 22,19,26
187 21,20,26 237 19,18,27 287 25,27,18
188 32,31,28 238 22,20,20 288 780,20000,18000
189 28,27,26 239 28,31,30 289 22,23,28
190 500,9000,10000 240 25,25,26, 290 21,28,20
191 22,22,22 241 24,28,25 291 28,19,31
192 23,19,27 242 20,20,25 292 29,19,19
193 18,19,18 243 22,31,27 293 26,30,19
194 21,29,30 244 22,30,19 294 31,28,23
195 29,22,21 245 29,26,29 295 22,20,23
196 27,19,18 246 22,21,24 296 23,21,19
197 29,29,27 247 28,30,20 297 29,20,22
Table 2
Conﬁrmatory assay results for mAbX.
Sample Reduction in ECL signal (%) Sample Reduction in ECL signal (%) Sample Reduction in ECL signal (%)
1 75,73,75 98 53,63,61 205 80,81,76
11 31,52,53 106 67,64,70 210 69,57,54
22 9,10,5 112 59,58,49 233 81,78,78
25 32,41,44 122 49,52,64 251 59,60,58
30 60,62,59 132 58,67,57 254 58,52,79
31 21,57,27 144 71,72,69 265 49,47,48
50 18,69,76 152 73,74,79 266 68,71,59
53 56,73,81 160 53,49,51 277 70,65,49
61 60,61,57 171 79,80,68 282 46,45,41
72 87,89,84 175 75,75,80 288 60,40,45
97 59,63,66 190 74,69,59
Table 3
Neutralization assay results for mAbX.
Sample Absorbance (% of uninhibited value) Sample Absorbance (% of uninhibited value) Sample Absorbance (% of uninhibited value)
1 40,40,80 106 49,46,39 210 78,41,23
11 98,80,82 112 58,56,90 233 83,76,73
25 95,79,81 122 70,67,64 251 76,51,45
30 83,78,80 132 80,65,58 254 78,57,95
31 98,97,98 144 79,74,80 265 82,76,72
50 97,98,95 152 76,75,73 266 89,85,70
53 90,49,91 160 54,65,74 277 78,47,41
61 89,48,40 171 77,67,49 282 40,31,9
72 97,95,96 175 79,83,86 288 80,39,40
97 50,43,39 190 81,62,60
98 57,47,40 205 83,76,71
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night incubation. After washing and blocking, samples (positive and
negative controls, patient serum samples) were added to the wells
and incubatedprior towashing and incubationwithHRP conjugated
antibody speciﬁc for human IgM, IgA and IgG. After furtherwashing,
substrate was added and the absorbance read using an automated
plate reader. Background signal was subtracted from all values.b) Conﬁrmation (ELISA competition mAbY)
This was carried out as for the screening assay except samples
were incubated for 1 h with an excess of unlabelled mAbY prior to
addition to mAbY coated wells.
Continuing with the tiered approach [6], conﬁrmed positives
were assessed for neutralizing capacity using the following assays:
Table 4
Clinical responses observed for patients with neutralizing antibodies for mAbX.
Sample Clinical observations Sample Clinical observations Sample Clinical observations
1 Impaired response 106 Impaired response 210 Impaired response
11 No effect on response 112 Impaired response;
recovering
233 Slight impaired response
25 No effect on response. Site reaction 122 Impaired response 251 Impaired response
Site reactions
Anaphylaxis
30 Slight impaired response 132 Impaired response 254 Impaired response;
recovering
31 No effect 144 Impaired response 265 Slight impaired response
50 Site reaction 152 Impaired response 266 Slight impaired response
53 Transient impaired response 160 Impaired response 277 Impaired response
61 Impaired response 171 Impaired response
Site reaction
282 Impaired response
72 No effect 175 Slight impaired response 288 Impaired response
97 Impaired response
Anaphylactoid & site reactions
190 Impaired response
98 Impaired response 205 Slight impaired response
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cytometry
For this, B cells were puriﬁed from peripheral blood mono-
nuclear cells (PBMCs) using magnetic beads coupled with a mAb
speciﬁc for CD19. For the assay, cells were incubated with ﬂur-
ochrome labelled mAbY which had been mixed with samples
(positive and negative controls, patient serum samples) for 1 h and
after washing analysed by ﬂow cytometry.
2. A cytolytic assay using Nalm6 cellsTable 5
Screening assay for mAbY trial A.
Sample Absorbance Sample Absorbance Sample Absorbance
1 <0.1, <0.1 35 <0.1, 0.6 69 <0.1, <0.1
2 <0.1, <0.1 36 0.4, >2.0 70 <0.1, <0.1
3 0.8, 1.4 37 <0.1, 0.4 71 0.4, >2.0
4 <0.1, <0.1 38 <0.1, <0.1 72 <0.1, <0.1
5 <0.1, <0.1 39 <0.1, <0.1 73 <0.1, <0.1
6 <0.1, <0.1 40 1.0, 1.1 74 <0.1, 1.4
7 0.2, 0.7 41 <0.1, <0.1 75 0.2, 1.8
8 <0.1, <0.1 42 <0.1, <0.1 76 <0.1, <0.1
9 <0.1, <0.1 43 <0.1, <0.1 77 <0.1, <0.1
10 <0.1, <0.1 44 <0.1, 0.8 78 0.3, >2.0
11 0.5, 1.8 45 0.2, 1.7 79 <0.1, <0.1
12 <0.1, <0.1 46 <0.1, <0.1 80 <0.1, <0.1
13 <0.1, <0.1 47 <0.1, <0.1 81 0.3, 1.8
14 0.3, >2.0 48 <0.1, <0.1 82 1.0, 1.2
15 <0.1, <0.1 49 0.2, >2.0 83 <0.1, <0.1
16 <0.1, 0.3 50 <0.1, <0.1 84 <0.1, <0.1
17 <0.1, <0.1 51 <0.1, <0.1 85 <0.1, 0.7
18 <0.1, <0.1 52 <0.1, <0.1 86 <0.1, <0.1
19 <0.1, <0.1 53 <0.1, <0.1 87 <0.1, <0.1
20 <0.1, <0.1 54 0.3, 1.7 88 0.3, >2.0
21 <0.1, <0.1 55 <0.1, <0.1 89 <0.1, <0.1
22 <0.1, <0.1 56 <0.1, <0.1 90 <0.1, <0.1
23 <0.1, 0.5 57 <0.1, 1.2 91 <0.1, <0.1
24 <0.1, <0.1 58 <0.1, <0.1 92 <0.1, <0.1
25 <0.1, 0.9 59 <0.1, <0.1 93 <0.1, 0.3
26 <0.1, <0.1 60 <0.1, <0.1 94 0.2, 1.7
27 <0.1, <0.1 61 <0.1, <0.1 95 <0.1, <0.1
28 0.4, 1.9 62 0.4, 2.0 96 <0.1, <0.1
29 <0.1, <0.1 63 <0.1, <0.1 97 1.1, 1.2
30 <0.1, <0.1 64 <0.1, <0.1 98 <0.1, <0.1
31 <0.1, 0.7 65 1.0, 0.9 99 <0.1, <0.1
32 <0.1, <0.1 66 <0.1, <0.1 100 <0.1, <0.1
33 <0.1, <0.1 67 0.3, 1.9 101 0.3, >2.0
34 <0.1, <0.1 68 <0.1, <0.1 102 <0.1, <0.13. An antibody-dependent cell-mediated cytotoxicity (ADCC)
assay
Two human antisera against mAbY were available from a small
phase 1 trial conducted with mAbY. Animal sera were also raised
using mAbYas immunogen. These were used to validate the assays.
The background readout of these assays was established by
assaying 50 serum samples obtained from ‘normal’ individuals.
Three of these sera showed atypically high absorbance values in the
screening assay and so were excluded from the analysis.
For immunogenicity assessment, a study was conducted using
serum samples collected from leukaemia patients who were taking
part in two clinical efﬁcacy trials. The trials included 102 and 60
patients respectively and blood samples were taken on 2 subse-
quent occasions 7 days after administration of mAbY product.
Serum was separated as soon as possible after venepuncture and
stored in aliquots at 40 C prior to analysis. Serumwas assayed at
a dilution of 1:25.
For the screening assay an absorbance reading of above 0.1 was
considered positive.
Data from this is shown in Tables 5 and 6. 12 patients had an-
tibodies tomAbYprior to treatment; thesewere not included in the
studies. Data were assessed to establish: a) assay performance; b)Table 6
Screening assay for mAbY trial B.
Sample Absorbance Sample Absorbance Sample Absorbance
1 <0.1, <0.1 21 1.1, 1.2 41 <0.1, <0.1
2 <0.1, <0.1 22 <0.1, <0.1 42 0.4, >2.0
3 <0.1, <0.1 23 <0.1, <0.1 43 <0.1, <0.1
4 <0.1, <0.1 24 <0.1, <0.1 44 <0.1, <0.1
5 <0.1, <0.1 25 <0.1, <0.1 45 <0.1, <0.1
6 <0.1, <0.1 26 <0.1, <0.1 46 <0.1, <0.1
7 <0.1, <0.1 27 <0.1, <0.1 47 <0.1, <0.1
8 1.0, 1.5 28 0.2, >2.0 48 <0.1, <0.1
9 <0.1, <0.1 29 <0.1, <0.1 49 <0.1, <0.1
10 <0.1, <0.1 30 <0.1, <0.1 50 0.3, 1.8
11 <0.1, <0.1 31 <0.1, <0.1 51 <0.1, 0.5
12 <0.1, <0.1 32 <0.1, <0.1 52 <0.1, <0.1
13 <0.1, <0.1 33 <0.1, <0.1 53 <0.1, <0.1
14 <0.1, <0.1 34 1.9, 1.8 54 <0.1, <0.1
15 <0.1, <0.1 35 <0.1, <0.1 55 <0.1, 0.9
16 <0.1, <0.1 36 <0.1, <0.1 56 <0.1, <0.1
17 <0.1, <0.1 37 0.2, 1.9 57 <0.1, 0.2
18 <0.1, <0.1 38 <0.1, <0.1 58 <0.1, <0.1
19 <0.1, <0.1 39 <0.1, <0.1 59 <0.1, <0.1
20 <0.1, <0.1 40 <0.1, <0.1 60 <0.1, 0.6
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c) any problems with samples/the assay.
Positive sera from the screen were conﬁrmed or not using the
conﬁrmatory assay. Results of this are shown in Tables 7 and 8. The
data were assessed to establish: a) assay performance; and b) how
many of the positive individuals in the screening assays are
conﬁrmed positive. A reduction in absorbance of greater than 20%
compared to uncompeted absorbance was considered a conﬁrma-
tion of positivity.
The conﬁrmed positive samples were assessed for neutralizing
capacity using the ﬂow cytometry assay described above. A
reduction in ﬂuorescence of >10% of the uninhibited value was
considered a positive result. Results of this are shown in Tables 9
and 10. The data were assessed to establish: a) assay perfor-
mance; and b) how many of the conﬁrmed positive individuals in
the screening assay produce neutralizing responses. Those found
positive were also assessed using the cytolytic and ADCC assays.
Samples found positive in the ﬂow cytometry assay were also
positive in the cytolytic and ADCC assays, whereas samplesTable 7
Conﬁrmatory assay results for mAbY trial A.
Sample Reduction in absorbance (%) Sample Reduct
3 35,45 37 2,79
7 92,94 40 5,7
11 5,8 44 0,60
14 27,61 45 67,55
16 90,90 49 61,41
23 89,87 54 68,40
25 0,45 57 0,10
28 10,9 62 83,46
31 4,47 65 1,4
35 7,34 67 76,43
36 55,63 71 69,48
Table 8
Conﬁrmatory assay results for mAbY trial B.
Sample Reduction in absorbance (%) Sample Reduct
8 11,9 37 82,51
21 8,12 42 79,49
28 80,54 50 69,41
34 6,8 51 0,80
Table 9
Neutralization assay results for mAbY trial A.
Sample Fluorescence (% of uninhibited value) Sample Fluorescence (
3 36,41 36 80,30
7 99,94 37 95,91
14 87,43 44 96,90
16 97,96 45 90,37
23 96,78 49 89,29
25 95,69 54 97,91
31 99,80 62 89,42
35 97,75 67 87,30
Table 10
Neutralization assay results for mAbY trial B.
Sample Fluorescence (% of uninhibited value) Sample Fluorescence (
28 92,45 50 95,93
37 94,54 51 96,81
42 91,33 55 95,75negative in the ﬂow cytometry assay were also negative in the
cytolytic and ADCC assays.
3.2.2. Correlation of antibody induction with clinical effects of
mAbY
Some patients showed diminished response to therapy as
treatment progressed as shown in Tables 11 and 12. The informa-
tion in Tables 11 and 12 was used to assess whether antibody
development causes such clinical effects as well as what the clinical
effects are caused by, i.e. binding antibodies or neutralizing
antibodies.
4. Evaluation of the case studies and key discussion points
4.1. Outcomes from the groups
4.1.1. mAbX
The groups noted correctly the incidence of positivity shown by
the screening assay as 11%. All but 1 samplewas conﬁrmed positive,ion in absorbance (%) Sample Reduction in absorbance (%)
74 0,45
75 0,11
78 77,41
81 69,50
82 1,2
85 76,64
88 55,47
93 0,2
94 88,51
97 7,11
101 80,42
ion in absorbance (%) Sample Reduction in absorbance (%)
55 0,66
57 0,0
60 0.82
% of uninhibited value) Sample Fluorescence (% of uninhibited value)
71 88,29
74 100,92
78 87,30
81 83,34
85 99,57
88 97,93
94 97,98
101 89,21
% of uninhibited value) Sample Fluorescence (% of uninhibited value)
60 98,91
Table 11
Clinical responses observed for patients with neutralizing antibodies for mAbY-trial A (patients with non-neutralizing antibodies showed no serious clinical effects).
Sample Clinical observations Sample Clinical observations Sample Clinical observations
3 Impaired response 36 Impaired response 78 Impaired response
14 Impaired response 45 Impaired response 81 No effect on response
23 No effect on response 49 Impaired response 85 No effect on response
25 No effect on response 62 Impaired response 101 Impaired response
31 No effect on response 67 Impaired response
35 No effect on response 71 Impaired response
Table 12
Clinical responses observed for patients with neutralizing antibodies for mAbY-trial B (patients with non-neutralizing antibodies showed no serious clinical effects.
Sample Clinical observations Sample Clinical observations Sample Clinical observations
28 Impaired response 42 Impaired response 55 Slight impaired response
37 Impaired response 51 No effect on response
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not subject to detection of high numbers of false positives. The
groups thought that more information about the assay was needed
especially on validation, positive and negative controls, sensitivity,
speciﬁcity and the statistical approach adopted. The number of
patients included may be too few to produce conclusive data and
the length of follow up needs to be at least 1 year to produce
deﬁnitive data. First assessment at week 14 may be too late; some
patients may have been missed.
The groups noted that the neutralization assay showed that
most (all but 3) of the conﬁrmed positive patients produced
neutralizing antibodies. One group questioned the use of a
competitive ligand binding assay rather than a cell based assay.
The neutralization data correlated quite well with observed
clinical effects. General effects included impaired response to
mAbX and in some instances anaphylactic responses.
It was considered that these effects are most likely induced by
the neutralizing antibodies.
Results in Tables 1e4 suggest that it is important to look at the
raw data for each individual subject to fully assess the impact of
immunogenicity on efﬁcacy/safety. It is also important to consider
concomitant treatments and comorbidities. For example, a com-
mon concomitant treatment is with the use of methotrexate which
has potent immunosuppressive effects and can complicate the
interpretation of immunogenicity assays.
The groups considered that overall, the study and assays used
were suitable for purpose (with the above mentioned reservations)
and that the detected immunogenicity was acceptable and did not
predict serious problems with the clinical use of mAbX in rheu-
matoid arthritis.
However all groups considered that the proposed increase in
clinical indications to include treatment of Crohn's disease and IBD
would require new immunogenicity studies conducted with such
patients. This is because incidence of immunogenicity is usually
higher in Crohn's disease and IBD compared to rheumatoid
arthritis, primarily because of treatment of the latter with
immunosuppressives.
4.1.2. mAbY
The groups were concerned that the screening assay detected 12
patients as being antibody positive before they began treatment
and questioned its validity for use with mAbY. The format used (a
direct ELISA) was considered inappropriate. This was substantiated
by the relatively high number of unconﬁrmed positives (9 out of 33
for trial A and 4 out of 11 for trial B). More information is needed on
the assay e.g. how the dilution of sample used was selected. Theassay is likely to be affected by residual mAbY in the sample,
particularly as sampling was started so soon after administration of
product. A different screening assay format should therefore be
adopted e.g. a bridging assay and the sampling time may need
lengthening.
Exclusion of the 12 patients with apparently pre-existing anti-
bodies to mAbY from the dataset was questioned.
The format of neutralizing antibody assays was found accept-
able. The perfect correlation between the cell binding assay and the
effector function assays supported the use of the cell binding assay
to measure neutralizing antibody.
Some differences were noted between the results from the two
trials. These may be due to the numbers of patients included,
concomitant treatments, and other factors.
Given the ﬂaws in the study design and the inappropriate
screening assay used, the groups found that the results were
difﬁcult to interpret. However, for a population of immunosup-
pressed patients, the antibody incidence was considered to be
high, in particular up to 16% with neutralising antibodies.
Although the data provided to assess their clinical impact were not
considered sufﬁcient (no results in antibody-negative patients and
especially because the method used to measure anti-leukaemia
response was not speciﬁed), neutralizing antibodies seemed
potentially associated with impaired treatment response in up to
10% of the patients, which was not considered acceptable in the
clinical context.
The groups considered that longer studies (possibly as follow-
ups) would be necessary to provide a more accurate assessment
of immunogenicity and its consequences.
Overall, the groups considered that the design of the study was
in part ﬂawed by the inappropriate screening assay and other issues
mentioned above. However, the limited data provided suggested
that unwanted immunogenicity was a signiﬁcant problemwith the
use of mAbY in the patient groups studied and would compromise
licensing.
All groups were of the opinion that the widening of clinical
indication to include treatment of autoimmune patients would
require additional immunogenicity studies conducted with these
patients. This is because of differences in immune status between
the patient groups as well as the deﬁciencies in the current study.
Data from immunosuppressed leukaemia patients are not infor-
mative for these other indications, and for a new product, it was
considered that immunogenicity should be studied in all in-
dications. Given the high immunogenicity of the product in
leukaemia patients, the groups did not recommend pursuing its
development for treatment of autoimmune diseases.
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The case study for mAbX is generally satisfactory. The assays
used are ﬁt-for-purpose.
The screening assay shows that 11% of patients produced anti-
bodies and none were positive before treatment. All but 1 of these
was conﬁrmed positive, with the one false positive being due to a
single positive sample in the screening assay (probably an error).
Only 3 of the conﬁrmed positives were non-neutralizing (10% of the
total were neutralizing) and this correlated well with impaired
response to treatment (9% of the total showed reduced response to
product). Site reactions also seemed correlated with antibody
development, although all antibody positive patients did not
experience them. In conclusion, the immunogenicity study for
mAbX is satisfactory and little more need be done from the
immunogenicity perspective. One omission was however the pro-
vision of clinical data from antibody negative subjects. This has
been included in the study described in this paper. The immuno-
genicity data does not cause concern for the clinical use of mAbX in
rheumatoid arthritis.
But use in Crohn's disease and IBD will require additional
immunogenicity studies for the reasons outlined in the outcomes
from the groups section above.
This contrasts with the situation for mAbY. The screening assay
used is not ﬁt for purpose; it produces positive results for a sig-
niﬁcant number of patients before they are treated and shows a
high level of false positives. This problem limits the value of the
immunogenicity study. The neutralization assay is reasonable and
correlated with results produced using bioassays.
The relatively high conﬁrmed immunogenicity detected, espe-
cially in trial A (24%) is of concern especially as a high proportion
(16%) of these patients produced neutralizing antibodies. The ma-
jority (63%; 10% of total) of patients with neutralizing antibodies
showed an impaired response to treatment with mAbY. The lack of
occurrence of any anaphylactoid incidences is unanticipated and
might be due to a deﬁciency in reporting. An omission is the pro-
vision of clinical data from antibody negative subjects. In conclu-
sion, the immunogenicity study for mAbY is not satisfactory
principally because of the use of a poor, probably invalid screening
assay. However the data produced suggests that mAbY produces
unacceptably high immunogenicity, with a relatively large pro-
portion of patients producing neutralizing antibodies which impair
clinical response to the product. This may have adverse conse-
quences for the licensing of the product.
Use of mAbY in autoimmune patients would require additional
immunogenicity assessment in the patients due to deﬁciencies in
the conducted study and differences in the immune status of the
different patient groups.
Experience with conducting the case studies at the 1st imple-
mentation workshop in Seoul showed that the groups of partici-
pants were able to assess the studies and formulate criticisms
concerning study design, assays used and implications of the
immunogenicity on clinical use and appropriateness of approving
the mAb products for licensing.
5. Lessons learnt during the case studies
Opinions expressed in previous workshops clearly indicated
that assessment of unwanted immunogenicity is not well under-
stood by several regulatory agencies. How to conduct studies was
also often unclear. Making decisions concerning the implications of
immunogenicity for product safety and efﬁcacy were not always
easy, especially when this is part of the licensing approval process.
Participants in the WHO implementation workshop held in 2010
[11] expressed an interest in immunogenicity as a topic whichshould be further considered in future workshops. In response to
this, the case studies described in this article were prepared. Active
participation in the case study exercises should assist regulators
and manufacturers to have better understanding of the concept of
immunogenicity, opportunities and limitations in generating rele-
vant data and interpretation of the results. After completing the
study, participants should have an understanding of how studies
are conducted, assessed and information obtained used to make
decisions relating to the appropriateness of the studies and how the
observed immunogenicity impacts on clinical use of the mAb
products. It is expected that completion of case studies would
provide a better understanding of the decision making process and
the impact that the immunogenicity studies may have in terms of
licensing.
Immunogenicity assessment principles, including antibody
assay descriptions plus appropriate utilization, were presented to
the workshop participants to set the scene for the case studies.
Regulators and manufacturers were asked to review the case study
data focusing on the questions mentioned under the Methodology
section of this article. They were invited to consider principles
outlined in the WHO Guidelines on the Quality, Safety and Efﬁcacy
of Biotherapeutic Protein Products Prepared by Recombinant DNA
Technology [5] and to apply them to the case study scenario.
Among many issues that were discussed, selected points described
below are provided as a set of key lessons learnt during the case
study exercise.
Themain important aspects of immunogenicity in the context of
biotherapeutic products in general, and monoclonal antibodies in
particular were elaborated before starting the case study exercise.
Immunogenicity is usually observed as appearance of antibodies
following the administration of a biotherapeutic product. There-
fore, a clear understanding of the immune response in such cases is
essential. As outlined in the WHO Guidelines mentioned above,
rDNA-derived biotherapeutic products may induce unwanted
humoral and/or cellular immune responses in recipients [5]. It is
also stated that immunogenicity should be investigated in the
target population since animal testing and in vitro models cannot
predict the immune response in humans. Factors that inﬂuence the
immune response such as nature of the drug substance, product-
and process-related impurities, excipients, route of administration,
dosing regimen, and speciﬁc issues related to a patient, disease and
therapy in question were also elaborated as a starting point for
review for the case studies. A number of details regarding the as-
says, testing procedures and interpretation of results were also
provided. Discussion on these aspects was focused on the questions
raised by the workshop participants regarding the following: 1) the
impact of the nature of antibodies on the deﬁnition of high and low
risk; 2) cut-points in conﬁrmatory assays and 3) preference for
using ﬁxed or ﬂoating cut off points. These issues were elaborated
in a presentation that was given before case study practice [10].
Suitability of the assays for immunogenicity assessment was
one of the topics of critical importance for conducting the case
study. It was expected that the workshop participants would be
familiar with the strategy for antibody testing which was brieﬂy
explained in the WHO Guidelines [5]. The case studies provided an
opportunity to understand that the selection, assessment and
characterization of assays, the identiﬁcation of appropriate sam-
pling time points, storage and processing of samples as well as
methods for statistical analysis of data all need to be justiﬁed.
Validation of the assays and assay sensitivity and speciﬁcity was
also discussed and participants reached a consensus on the validity
and robustness of the assays in each case study. The assumption
was that the assays are valid, sensitive and speciﬁc for the intended
purpose. This is an area where the expertise of participants plays a
crucial role in applying general guiding principles to a speciﬁc case
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bodies against mAb was recognized in the WHO document and the
examples elaborated here illustrate some of technical challenges in
that regard.
Several aspects of the study design were questioned by the
workshop participants. In line with WHO Guidelines [5], it is clear
that the sampling time points in immunogenicity testing depend
on the expected appearance of antibodies and their clinical con-
sequences. One of the important lessons learnt was how to assess
the impact of neutralizing antibodies on efﬁcacy and safety. Ques-
tions that the workshop participants raised regarding the false
positive and false negative results and the interpretation of
neutralizing antibody data with or without clinical consequences
were very useful for clarifying the meaning of such ﬁndings in
different scenarios. The value of reviewing raw data for each indi-
vidual subject in order to assess the impact of immunogenicity on
efﬁcacy and safety was clearly demonstrated in the case studies.
The duration of the monitoring period for immunogenicity
testing was one of the critical questions that was addressed. It is
stated in the WHO Guidelines that the monitoring period depends
on the intended duration of treatment and the expected time of
antibody development [5]. One of the examples in the case studies
illustrated that a longer period of observation may be necessary to
increase accuracy in assessing immunogenicity.
Discussion on additional indications and a need for additional
immunogenicity studies in such cases required a very good un-
derstanding of the proposed treatments, differences in terms of the
immune status in various patients' groups and the limitations of the
current studies. Pros and cons regarding the additional immuno-
genicity studies revealed that the expectations in terms of the size
and design of such studies differ among regulators and manufac-
turers. Nevertheless, a clear consensus that appropriate data needs
to be generated to support proposal for additional indications was a
good sign that the participants recognized the limitations of the
original studies that were conducted.
Immunogenicity assessment of monoclonal antibodies requires
an expertise in multiple areas of science as well as solid experience
in regulatory evaluation of these complex biologicals. When it
comes to biosimilar monoclonal antibodies, it becomes an even
more sophisticated exercise, including some challenges of
addressing correlation between bioanalytical signals and clinical
endpoints [12]. Useful explanations with some practical consider-
ations on demonstration of similarity of monoclonal antibodies in
terms of quality and efﬁcacy were provided in the case studies that
are published elsewhere [13,14]. Comparative design of efﬁcacy
trials is necessary for assessing immunogenicity of a similar bio-
therapeutic product (SBP) in comparison with the reference bio-
therapeutic product (RBP). As stated in WHO Guidelines on
evaluation of SBPs [15], if the manufacturer intends to extrapolate
efﬁcacy and safety data to other approved indications of the RBP,
care should be taken to ensure that immunogenicity is investigated
in the patient population that carries the highest risk of developing
an immune response and immune-related adverse events. Given
the limited size of clinical trials that are conducted pre-licensure, a
speciﬁc risk management plan for an SBP needs to be addressed at
the time of licensure. Good understanding of the immunogenicity
data that are needed and a feasibility for generating these data is an
important foundation for regulators to make an appropriate
judgement regarding the suitability of a product for licensing but
also for post-approval monitoring.
The regulatory decision making process is a rather complex
issue for many regulators around the world. Scientiﬁc evidence as a
basis for regulatory decisions is not always available. Such decisions
require a certain level of judgement on a case-by-case basis with
careful consideration of all the relevant factors. It is difﬁcult toanswer particular practical questions in WHO Guidelines or guid-
ance issued by other bodies. Therefore, the value of case studies is
heavily dependent on the interest and active involvement of the
workshop participants. In this particular case, all participants
expressed a great interest and provided an excellent input to the
discussion.
6. Conclusions
Immunogenicity assessment is one of the regulatory tasks
which include review of immunogenicity studies and the inter-
pretation of the results. The appropriate interpretation of immu-
nogenicity data is one of the critical parameters for deﬁning the
safety proﬁle of a monoclonal antibody. It is also important for
addressing the need for post-marketing surveillance. Potential
consequences of inappropriate interpretation of immunogenicity
data include 1) conclusions that create an obstacle for licensing a
product with a safety proﬁle which is suitable for the intended use
and 2) licensing of a product with a problematic safety proﬁle.
The case studies provided in this paper show the importance of
being able to assess raw data and drawing correct conclusions from
the results obtained. They emphasise the usefulness of the tiered
approach to immunogenicity assessment recommended in several
publications/guidelines [1,2,5,6,16].
The studies highlight the need to assess the methods used for
appropriateness for use for their intended purpose and to interpret
the data generated, taking account of their limitations. The case
studies allow conclusions to be drawn concerning the methods
used, their relative merits and whether the immunogenicity
revealed by the studies impacts on the clinical use of the mAb
products considered. These case study examples can be publically
discussed and used for the purpose of providing training on the
approach taken for assessing the unwanted immunogenicity of
mAb products and other biotherapeutics.
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